v3.26.1
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 11 – SEGMENT INFORMATION

 

We manage our business activities on a consolidated basis and operate as a single operating segment dedicated to developing and marketing products for various medical conditions. We derive our revenue from product sales of the AlloRx™ and AlloEx product lines. The accounting policies of the segment are the same as those described in Note 1 – Nature of Organization and Summary of Significant Accounting Policies.

 

Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer, Chris Furman. The CODM uses net loss, as reported in our consolidated statements of operations, in evaluating the performance of the segment and determining how to allocate our resources as a whole. The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented.

 

The following table presents the operating results of the segment:

 

  

Three Months

Ended

January 31, 2026

  

Three Months

Ended

January 31, 2025

 
Revenues  $529,417   $449,874 
Less Significant Segment Expenses:          
Cost of Sales   (117,463)   (93,092)
Total Compensation and Benefits Cost   (443,527)   (425,217)
Research and Development   (169,221)   (73,883)
Impairment Expense   (99,700)   - 
All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based Compensation) (a)   (583,195)   (1,249,913)
Other Segment Items:          
Depreciation, Amortization and Stock-Based Compensation   (308,253)   (453,287)
Interest Expense   (502,730)   (103,693)
Other Income (Expense), Net   587,704    (885,451)
           
Consolidated Net Loss  $(1,106,968)  $(2,834,662)

 

  (a) All other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.